Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof

A method for treating a PD-L1 mediated disease or disorder in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein:

• (i) the heavy chain variable region comprises a heavy chain CDR1 (HCDR1) of NDYWX1 (SEQ ID NO:
• 10), a heavy chain CDR2 (HCDR2) of YISYTGSTYYNPSLKS (SEQ ID NO:
• 11) and a heavy chain CDR3 (HCDR3) of SGGWLAPFDY (SEQ ID NO:
• 12);
• and
• the light chain variable region comprises a light chain CDR1 (LCDR1) of KSSQSLFYX2SNQKX3SLA (SEQ ID NO:
• 13), a light chain CDR2 (LCDR2) of GASTRES (SEQ ID NO:
• 14) and a light chain CDR3 (LCDR3) of QQYYGYPYT (SEQ ID NO:
• 15);
• wherein X1 is T, X2 is H and X3 is H;
• or
• (ii) the heavy chain variable region comprises a heavy chain CDR1 (HCDR1) of SYWMH (SEQ ID NO:
• 16), a heavy chain CDR2 (HCDR2) of RIX4PNSG X5TSYNEKFKN (SEQ ID NO:
• 17) and a heavy chain CDR3 (HCDR3) of GGSSYDYFDY (SEQ ID NO:
• 18);
• and
• the light chain variable region comprises a light chain CDR1 (LCDR1) of RASESVSIHGTHLMH (SEQ ID NO:
• 19), a light chain CDR2 (LCDR2) of AASNLES (SEQ ID NO:
• 20) and a light chain CDR3 (LCDR3) of QQSFEDPLT (SEQ ID NO:
• 21);
• wherein X4 is G, and X5 is F.